Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.
Contact us to learn how Vital Transformation can help your organisation.
LATEST RESEARCH
LATEST COMMUNICATIONS
![bsbh-vt-logo-x2](https://vitaltransformation.com/wp-content/uploads/2018/05/bsbh-vt-logo-x2-300x58.png)
Our Communication Services
With the continuing pressure placed upon the US biopharma sector from Washington DC, how is the California biopharma ecosystem, arguably the leading hub for innovative biotech worldwide, responding? In this Vital Health Podcast, we speak with Joseph Panetta to discuss this issue. Joe is the President & CEO of Biocom California, an organization representing over 1,800 members working in California's life sciences sector to break down barriers to doing business and advocate for innovation. As the head of Biocom California since 1999, Joe is regarded as a thought leader in biotech and life sciences globally.
Find all our communication projects on Better Science, Better Health
MORE RESEARCH
Making Real World Data Real – New RWE Methodologies for HTAs
With the increasing use of accelerated regulatory tools like the Food and Drug Administration’s breakthrough designation, there are mounting challenges for European health technology assessors (HTAs) to make an accurate assessment of the long- term value and performance of many new therapies. Data presented in evidence is often extrapolated from outcomes six months or less, and what’s good enough for regulatory approval often doesn’t meet the needs for comparative effectiveness, value, and outcomes measures for HTAs. Vital Transformation’s recent BMJ publication demonstrates a novel, practical approach to harnessing electronic health records and RWE to help solve this problem. However, access to robust deidentified patient records in Europe is key.
Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants
18th July 2019
With the increasing demands being placed on HTAs in Europe, a methodology allowing for a valid assessment of the clinical effectiveness and costs for indications targeting small patient populations and orphan conditions, such as ALL, at the time of a reimbursement decision is vital. This is particularly true when the costs of these interventions are significantly high, such as in the case of CAR-T, where costs exceed US$375 000. By extracting RWD from live hospital EHRs, we were able to demonstrate a novel methodology that allows us to move beyond the use of proxies for clinical effectiveness measures extrapolated from clinical trials to obtain an assessment of the long-term outcomes and total costs of new therapies, such as CAR-T, compared with the next-best legacy treatment option.
Azar’s Plan To Tie U.S. Drug Prices To Foreign Ones Will Impact Investments In R&D
Photographer: Al Drago/Bloomberg © 2019 BLOOMBERG FINANCE LP Publish date: June 21, 2019 By John LaMattina, Contributor for Forbes Azar claims that HHS can reduce spending on Medicare Part B drugs with little impact on biopharmaceutical R&D investment. Duane Schulthess, Managing Director at VitalTransformation, questioned Azar’s claim on this. As he delved into specific compounds on Azar’s list of 27, he found some startling data. One striking case is with Biogen’s Multiple Sclerosis drug, Tysabri.
VITAL HEALTH PODCASTS
Our podcast series is also available via your favourite channels!
![]() |
![]() |
---|---|
![]() |
![]() |
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more...
VT on X
EU biopharma company startups declined 50% in 2018, well before the COVID pandemic #gplhttps://t.co/issED0DVJV@amgen @abbvie @abbvieuk @IAmBiotech @DuaneSchulthess @BSBHbyVT @VitalTransform pic.twitter.com/fORbCktE8z
— VitalTransformation (@VitalTransform) April 23, 2024
New study "The EU General Pharmaceutical Legislation & Clawbacks: Calculated impacts – both designed and unintended." https://t.co/issED0DnUn@amgen @AbbVie @IAmBiotech @DuaneSchulthess @BSBHbyVT @VitalTransform @abbvieuk
— VitalTransformation (@VitalTransform) April 18, 2024
Our clients include many of the world’s leading health care organisations.